Trump's New Drug Pricing Plan Isn't "The Best Deal" For Patients


By Kenneth E. Thorpe

President Trump will soon unveil a new plan to reduce drug prices.

The proposal would indeed slash Americans' pharmacy bills -- at least temporarily. But those savings would come at the expense of patients' access to cutting-edge drugs. The reform would also jeopardize future medical breakthroughs.

The administration's proposal would restructure Medicare Part B, which covers advanced, physician-administered medicines that treat serious chronic diseases like cancer and multiple sclerosis. On average, Part B drugs cost 80 percent more in the United States than in other developed countries.

Why do Americans pay more for the exact same medicines?

Simple -- the United States doesn't impose price controls on pharmaceuticals; other nations do. Many foreign regulatory agencies won't even make medicines available to patients unless manufacturers offer enormous discounts.

As a result, patients in those nations have fewer treatment options. Consider cancer therapies. Ninety-five percent of all oncology medicines approved anywhere in the world between 2011 and 2018 were available in the United States. By contrast, patients in the United Kingdom and France had access to only 74 percent and 65 percent of those treatments, respectively. Inexplicably, the Trump administration wants to copy Europe's anti-patient policies.

Under the administration's proposal, Medicare would reimburse doctors based on an "international pricing index" -- essentially an average of the prices paid in other countries, including Canada, France, and the United Kingdom.

Indexing Part B reimbursements to these countries' prices would effectively import their access restrictions too. It'd deprive the sickest, most vulnerable Americans of their medicines.

The proposal would also discourage medical innovation.

Drug development is a challenging, expensive endeavor. It costs almost $3 billion, on average, to bring just one new drug to patients. And nearly 90 percent of all medicines that enter clinical trials ultimately fail to win FDA approval.

But if the United States adopts price controls, companies won't pursue as many research projects. The meager potential returns wouldn't justify the considerable risks.

A slowdown in medical innovation would jeopardize U.S. health gains. In the past three decades, cancer death rates have fallen 27 percent. Roughly three-quarters of those survival gains are attributable to new medicines.

By limiting patients' access to existing drugs and discouraging the development of future ones, the proposal would make it harder for Americans to manage their conditions and avoid costly complications. According to a study by my organization, the Partnership to Fight Chronic Disease, new medicines could avoid $6 trillion in healthcare costs and prevent 16 million deaths by 2030.

The administration's proposal condemns Americans to the same life-threatening access restrictions that patients in other countries endure. It's a lousy deal.

Kenneth E. Thorpe is a professor of health policy at Emory University and chairman of the Partnership to Fight Chronic Disease.

More Resources


03/29/2024
2024, an Election About Elections
The new poll out from Fox News has a number of intriguing findings.

more info


03/29/2024
The Overlooked Truths About Biden's Age
In terms of optics and in terms of energy, I wish President Biden were younger. There's no point in pretending

more info


03/29/2024
Biden, Obama & Clinton Join Forces in NY


more info


03/29/2024
Meddlers for RFK Jr.


more info


03/29/2024
Will RFK Jr.'s Support for Israel Limit His Appeal on Left?


more info


03/29/2024
Joe Lieberman's Last Words on Israel


more info


03/29/2024
A Senator Who Loved To Kibitz


more info


03/29/2024
Behind Scenes Stories of Censorship


more info


03/29/2024
Bidenomics Is Making China Angry. That's OK
A persistent theme in Republican campaigning these past few years has been the effort to portray Democrats in general, and

more info


03/29/2024
Biden's Boss Tightens the Screws


more info


03/29/2024
The Fight To Flip the House Just Got Harder for Dems


more info


03/29/2024
In 2024, Digital Is Everything in Politics


more info


03/29/2024
Comer Sums Up His 'Evidence' of Biden Crimes. It's Scant


more info


03/29/2024
WaPo's Lead Liar Waves Away Evidence of Biden Corruption
Glenn Kessler pretended to 'dissect' Rep. James Comer's comments but did not challenge any of the evidence the Republican mentioned.

more info


03/29/2024
Sam Bankman-Fried's Dream Came True


more info



Custom Search

More Politics Articles:

Related Articles

The Future of Transportation Isn't Just Self-Driving Cars. It's Public Transit.


Fiat Chrysler and BMW just announced plans to jointly develop self-driving cars. The move puts the automakers in competition with Google, Apple, and other car manufacturers that are also working on driverless vehicles. The question is when, not if, this is going to be commonplace.

Hating Tom Brady? Who Will Be Able To Argue?


Millions of Americans will be glued to the television Sunday to watch the 52nd Super Bowl. Millions of Americans will not be watching for various reasons. Some are not interested in football. Some will have something else better to do. Others are sick and tired of the National Football League. Others are disappointed in multi-million dollar players kneeling during the National Anthem.

Another Budget Deal Bites the Dust


Back in September I wrote about our "ethically challenged" democratic system. I said, "We are caught in a downward, self-destructive [debt] spiral."

US Faces Fiscal Armageddon, and We Propose a One-Half of One Percent Solution


"The U.S. economy made a spectacular comeback in 2017. But the country still faces the prospect of fiscal Armageddon if we don't cut spending and check the out-of-control National Debt," says Dan Weber, president of the Association of Mature American Citizens [AMAC].

Protect American Ideas Through Trade


We take for granted that the "ordinary" things we use every day are in fact extraordinary inventions and breakthroughs that took years of investment, work, and commitment to bring to life.

John Skipper, Blackmail in America - Who needs that?


here is no such thing as buying someone's silence. Silence really doesn't exist. If people want to tell the world it's easy to do. Tell one other person in the world and if the information is grimy enough it will be retold a thousand or a million times. Bad news travels fast. Sordid news for some reason always rises to the top. Regardless of how hard you try to cover it, you can't.

A New NAFTA Must Halt Intellectual Property Theft


As American negotiators push to conclude NAFTA renegotiations, they should prepare to demand stronger protection of intellectual property rights. Robust IP protections would prevent Canada, Mexico, and other trading partners from freeloading off American ingenuity -- particularly our medicines.

Marx's Apologists Should Be Red in the Face


May 5 marked the bicentennial of Karl Marx, who set the stage with his philosophy for the greatest ideological massacres in history. Or did he?

Sec. Zinke's Offshore Plan Is On Point


Interior Secretary Ryan Zinke wants to vastly expand offshore oil and gas production -- and politicians from coastal states are livid.

American Seniors Deserve Better than Canadian Health Care


Seven in ten Democrats want to establish a Canada-style single-payer system. Progressive lawmakers are even more gung-ho.

The Free Market Is Curing Blindness


The FDA recently approved a revolutionary drug that could restore sight to 2,000 nearly-blind Americans.

EPA is Right to Applaud Oil and Natural Gas Companies


The Environmental Protection Agency recently released a much-anticipated report on greenhouse gas emissions. It contains some great news. Between 2015 and 2016 -- the last year measured -- U.S. emissions dropped 1.9 percent.

Trump's Drug Pricing Speech Mostly Hit the Right Notes


President Trump delivered a major speech from the White House Rose Garden on prescription drug prices this spring. He announced several policies aimed at reducing the overall cost of pharmaceuticals and limiting patients' out-of-pocket expenses.

Summit Asymmetries


On June 3, 1961, barely into the fifth month of his presidency, John F. Kennedy met with Soviet Premier Nikita Khrushchev. Kennedy requested the meeting in February as an "informal" opportunity to become better acquainted. Kennedy had risen rapidly through the American political hierarchy from the House of Representatives to the U.S. Senate and on to the presidency.

Envionmentalists are Lying About How Green Their Money Is


Some of America's most prominent environmentalist groups are secretly investing in oil and natural gas, even as they publicly push groups to divest from fossil fuels. That's the takeaway from an explosive new report from NBC.

Americans Fund Most of the World's Drug Research. Here's How Trump Can End That


President Trump recently released an ambitious, 44-page plan to drive down prescription drug prices. The blueprint relies, in part, on negotiating and enforcing trade deals to prevent other countries from freeloading off of American researchers.

Infant Health Deserves Careful Research, Not Partisan Bickering


Want to win a political argument? Accuse your opponent of hurting children.

"Environmentalism" Shouldn't be a Dirty Word for Republicans


Is there a more despised word among Republicans than "environmentalist"? For many GOP voters, the term conjures up a mental image of tree-hugging socialists hell-bent on regulating our country back to the Stone Age.

The Quite Coup of the Courts


There is a constitutional crisis in this country. One branch of government is undermining the rule of law.

No Matter How You Phrase It, Price Controls Are Bad For Patients


President Trump claims he's preparing an executive order on drug prices.